We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

280 hedge funds and large institutions have $7.98B invested in BioMarin Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 280 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

16% less call options, than puts

Call options by funds: $36.2M | Put options by funds: $43M

Holders
280
Holders Change
+280
Holders Change %
–
% of All Funds
9.14%
Holding in Top 10
7
Holding in Top 10 Change
+7
Holding in Top 10 Change %
% of All Funds
0.23%
New
280
Increased
–
Reduced
–
Closed
–
Calls
$36.2M
Puts
$43M
Net Calls
-$6.77M
Net Calls Change
-$6.77M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
O
26
OrbiMed
New York
$74.8M +$83.6M +1,341,200 New
GGHC
27
Gilder Gagnon Howe & Co
New York
$71.8M +$80.2M +1,287,612 New
Northern Trust
28
Northern Trust
Illinois
$62.2M +$69.5M +1,115,230 New
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$60.2M +$67.3M +1,079,906 New
HCM
30
Holland Capital Management
Illinois
$58.8M +$65.7M +1,054,555 New
Franklin Resources
31
Franklin Resources
California
$53.5M +$59.7M +958,165 New
Citadel Advisors
32
Citadel Advisors
Florida
$49.5M +$55.3M +886,990 New
UBS AM
33
UBS AM
Illinois
$47.5M +$53M +850,671 New
JP Morgan Chase
34
JP Morgan Chase
New York
$45.5M +$50.9M +817,024 New
UIM
35
USS Investment Management
United Kingdom
$45.3M +$50.7M +813,334 New
Ameriprise
36
Ameriprise
Minnesota
$44.9M +$50.2M +804,959 New
PAI
37
Palo Alto Investors
California
$43.9M +$49.1M +787,119 New
BBA
38
Baker Bros. Advisors
New York
$43.7M +$48.8M +783,311 New
Bank of New York Mellon
39
Bank of New York Mellon
New York
$42.2M +$47.1M +756,577 New
AllianceBernstein
40
AllianceBernstein
Tennessee
$41.4M +$46.2M +741,980 New
CCI
41
Columbus Circle Investors
$40.1M +$44.9M +720,055 New
First Trust Advisors
42
First Trust Advisors
Illinois
$40M +$44.8M +718,205 New
PI
43
Putnam Investments
Massachusetts
$34.8M +$38.8M +623,046 New
GIM
44
Granahan Investment Management
Massachusetts
$33.5M +$37.4M +600,400 New
Norges Bank
45
Norges Bank
Norway
$33.3M +$37.2M +597,008 New
Geode Capital Management
46
Geode Capital Management
Massachusetts
$31.6M +$35.3M +565,682 New
TCIM
47
TIAA CREF Investment Management
New York
$31.2M +$34.8M +558,956 New
CS
48
Credit Suisse
Switzerland
$29.6M +$33.1M +530,665 New
MAA
49
Managed Account Advisors
New Jersey
$29.2M +$32.6M +523,404 New
RFS
50
Rockefeller Financial Services
New York
$28.1M +$31.4M +503,752 New
1
2
3 4 5

BMRN Hedge Fund Activity: Q2 2013 in Review

280 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2013, worth a combined $7.98B.

Buyers outnumbered sellers: 280 funds opened new BMRN positions and 0 closed out — a net gain of 280 holders — while 0 added to existing stakes and 0 trimmed.

  • 280 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $7.98B of BioMarin Pharmaceuticals stock for Q2 2013.
  • 280 funds opened new BioMarin Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +280 holders.

Based on aggregated 13F filings for Q2 2013.